Arkolith/Insider Trading/AARD/Form 4

Decheng Capital Global Life Sciences Fund IV, L.P.

10% OwnerAardvark Therapeutics, Inc. (AARD) · full profile →Form 4 · filed Feb 19, 2025
Net Buying
Open-Market Buys
$20.0M
Open-Market Sells
$0
Net Open-Market Flow
$20.0M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 14, 2025Conversion(C)2.3M——2.3M
Feb 14, 2025Buy(P)625K$16.00$10.0M958K
Feb 14, 2025Buy(P)625K$16.00$10.0M3.0M
Feb 14, 2025Conversion(C)333K——333K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 14, 2025Conversion(C)19.8M—$00
Feb 14, 2025Conversion(C)2.8M—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-023409) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML